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Jaime Sanz,1,2 Miguel A. Sanz,1 Silvana Saavedra,1 Ignacio Lorenzo,1 Pau Montesinos,1
Leonor Senent,1 Dolores Planelles,3 Luis Larrea,3 Guillermo Martın,1 Javier Palau,1
Isidro Jarque,1 Jesus Martınez,1 Javier de la Rubia,1 Federico Moscardo,1 Monica Romero,1
Irene Luna,1 Alberto Montava,1 Sergio Can˜abate,1 Guillermo F. Sanz1Clinical studies focused on disease-specific outcomes of cord blood transplant (CBT) from unrelated donors
are limited. We analyzed the outcome and prognostic factors of 49 adults with high-risk acute myelogenous
leukemia (AML) receiving single-unit CBT from unrelated donors after myeloablative (MA) conditioning at
a single institution. Conditioning regimens were based on the combination of thiotepa, busulfan (Bu), cyclo-
phospamide (Cy), or fludarabine (Flu), and antithymocyte globulin (ATG). Cumulative incidence of myeloid
and platelet engraftment was 96% and 73% at a median time of 20 and 62 days, respectively. Engraftment was
significantly faster for patients receiving higher doses of CD341 cells. Confidence Interval of graft-versus-
host disease (GVHD), acute GVHD (aGVHD) grade II-IV, III-IV, and extensive chronic GVHD (cGVHD)
were 26%, 15%, and 30%, respectively. Leukemia-free survival (LFS), nonrelapse mortality (NRM), and
relapse at 2 years were 42%, 39%, and 19%, respectively. Low number of total nucleated cells (TNC) had
a negative impact on NRM and LFS. Patients transplanted in first complete remission (CR1) receiving
TNC above 2  107/kg had a 4-year LFS of 75%. These results show that CBT from unrelated donors is
a curative treatment for a substantial number of patients with high-risk AML, particularly if transplant is per-
formed with highly cellular units in patients in first CR.
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Patients with high-risk acute myelogenous leuke-
mia (AML) have few chances of cure without
allogeneic hematopoietic stem cell transplantation
(HSCT). However, the application of this procedure
is limited by the availability of suitable human leuko-
cyte antigen (HLA)-compatible donors. Umbilical
cord blood (UCB) has emerged as an alternative stem
cell source for patients lacking HLA-matched adult
donors [1].
Clinical experience has shown that CB trans-
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provides at least similar survival in children with
acute leukemia [2,3]. For adults, registry-based stud-
ies have established CBT as a safe and feasible alter-
native to BMT when a matched sibling donor is not
available [4,5]. However, information on disease-
specific outcomes, in particular patients with AML
treated with CBT from UDs, is very limited. In
fact, it is restricted to 2 subsequent reports from
the University of Tokyo [6,7] plus 2 additional regis-
try-based reports, from Eurocord and the European
Blood and Marrow Transplant Group (EBMT) [4]
and from the Japan Marrow Donor Program
(JMDP) and the Japan Cord Blood Bank Network
(JCBBN) [8], both mainly focused on comparing
CBT with BMT in patients with acute leukemia, in-
cluding both AML and acute lymphoblastic leukemia
(ALL).
We here report the outcome of a series of adults
with AMLwho received CBT fromUDs at a single in-
stitution. Apart from confirming the safety and efficacy
of the procedure in this specific disease, an additional
aim of the study was to identify variables influencing
short- and long-term outcomes.
Table 1. Graft- and Transplantation-Related Characteristics*
Cord blood unit supplier, no. (%)
Barcelona Cord Blood (CB) Bank 10 (20)
Australian CB Bank 8 (16)
New York Blood Center 7 (14)
Others 24 (49.0)
HLA compatibility, no. (%)†
6 of 6 4 (8)
5 of 6 19 (39)
4 of 6 25 (51)
3 of 6 1 (2)
ABO blood group mismatch, no. (%)
Major 7 (13)
Minor 16 (33)
None 25 (52)
Donor-recipient sex match, no. (%)
Male-male 13 (27)
Male-female 9 (18)
Female-male 17 (35)
Female-female 10 (20)
KIR-ligand incompatibility in graft-versus-host
direction, no. (%)
Yes 14 (29)
No 35 (71)
Time elapsed between cord blood storage and
transplantation, mo
Median 48
Range 10-212
Year of transplantation, no. (%)
2000-2005 17 (35)
2006-2008 32 (65)
Conditioning regimen, no. (%)
TT + Bu + Cy + ATG† 16 (33)
TT + Bu + Flu + ATG‡ 33 (67)
Graft-versus-host disease prophylaxis, no. (%)
Cyclosporine A + Prednisone 37 (75)
Cyclosporine A + MMF 12 (25)
No. of nucleated cells before freezing,  107/kg
Median 2.7
Range 1.4-5.5
No. of nucleated cells infused,  107/kg
Median 2.2
Range 1.0-4.4
No. of CD34+ cells before freezing,  105/kg
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Eligibility Criteria
This report constitutes a retrospective review of
all 49 consecutive adult patients with AML who
underwent a CBT from unrelated donors at our insti-
tution between June 2000 and November 2009.
Patients were eligible for enrolment if they met the
following criteria: (1) high-risk AML, defined by
either high-risk cytogenetics or poor prognosis gene
markers, more than 1 cycle to achieve complete remis-
sion (CR), or disease status beyond first CR; (2) not
suitable related donor (HLA-identical or 1-antigen-
mismatched); (3) need for an urgent transplantation
or lack of HLA-identical UD after searching in the
international registries for no more than 3 months;
and (4) an available CB unit fulfilling minimum estab-
lished criteria for both HLA compatibility between
donor and recipient and cell dose. In this regard, CB
units had to share at least 4 HLA antigens with the
recipient (HLA class I antigens [A and B] determined
by serologic or low-resolution DNA typing and class
II antigens [DRB1] by high-resolution DNA typing).
As per cell dose, total nucleated cells (TNC) higher
than 1.5  107 per kilogram of the recipient’s body
weight were required until May 2006. Thereafter,
TNC higher than 2  107 per kilogram of the recipi-
ent’s body weight and CD341 cells higher than
1  105 per kilogram of the recipient’s body weight
were mandatory. The institutional review board ap-
proved the protocol, and written informed consent
was obtained from all patients according to the decla-
ration of Helsinki.Median 1.6
Range 0.17-4.05
No. of CD34+cells infused,  105/kg
Median 1.2
Range 0.09-6.09
HLA indicates human leukocyte antigen; KIR, killer cell immunoglobulin-
like receptor; TT, tiothepa; Bu, busulfan; Cy, cyclophosphamide; Flu, flu-
darabine; ATG, antithymocyte globulin; MMF, mycophenolate mofetil.
*Percentages may not sum to 100 because of rounding.
†Thiotepa 5 mg/kg/day on days29 and28, oral busulfan 1 mg/kg/6 h or
intravenous (i.v.) busulfan 0.8 mg/kg/6 h or on days27 to25, cyclophos-
phamide 60 mg/kg/day on days 24 and 23 and ATG on days 25 to 22
(Lymphoglobuline, Merieux, Lyon, France, 15 mg/kg/day; or Thymoglo-
bulin, Sangstat/Genzyme, Lyon, France, 2 mg/kg/day).
‡Thiotepa 5mg/kg/dayon days27 and26, i.v. busulfan 3.2mg/kg as a sin-
gle daily dose on days25 to23, fludarabine 50mg/m2/day on days25 to
23 and ATG (Thymoglobulin, 2 mg/kg/day on days25 to22 in 21 pa-
tients and 2 mg/kg/day on days24 to22 in the last 12 patients).CB Unit Selection and Management
The search of CB units was conducted by the
Spanish Registry of Bone Marrow Donors (Registro
Espan˜ol de Donantes de Medula Osea). Among the
available CB units fulfilling the minimum established
criteria, units with higher cell dose, considering both
TNC andCD341 cells, and higherHLA compatibility
were selected across the study period. Additionally,
ABO compatibility and year of storage were also con-
sidered. All CB units tested negative for human immu-
nodeficiency virus (HIV), hepatitis B and C viruses
(HBV, HCV), as well as human T cell lymphotropic
virus type I. All CB units and mothers were negative
for immunoglobulin M antibody to cytomegalovirus
(CMV).
Thawing of CB units was performed by Rubinstein
et al’s method [9], with minor modifications as
described elsewhere [10]. Before infusion, a sample
was drawn directly from the bag for cell counts, includ-
ing CD341 cells [11], cell viability, clonogenic assays
[12], and microbiology.Conditioning Regimen
Myeloablative (MA) conditioning regimens were
all based on the combination of thiotepa, busulfan
(Bu), cyclophospamide (Cy), or fludarabine (Flu), and
antithymocyte globulin (ATG) (Table 1). Until June
2006, 16 patients received thiotepa, Bu, Cy, and
ATG. From June 2006, Cy was substituted by Flu.
88 Biol Blood Marrow Transplant 16:86-94, 2010J. Sanz et al.Thirty-three patients received thiotepa, i.v. Bu as
a single daily dose, Flu, and ATG.
Graft-versus-host disease (GVHD) Prophylaxis
and Treatment
All patients received cyclosporine (CsA) 1.5mg/kg/
12 h i.v., followed by 3-5 mg/kg/12 h orally when oral
intake was possible, with slow tapering starting be-
tween day 190 and 1180 and discontinuation on day
1180 or before if feasible. CsA was combined with
prednisone in the first 37 patients (0.5 mg/kg/day on
days 17 to 114, 1 mg/kg/day on days 114 to 128,
with slow tapering to discontinue on day 1180) [13]
ormycophenolate-mofetil (MMF) 15mg/kg/12 h until
day128 in the following 12 patients.
Patients developing acute GVHD (aGVHD) re-
ceived high-dose methylprednisolone as initial therapy
(20 mg/kg/day; halving the dose every 3 days until
reaching 1 mg/kg/day, and then gradually tapered) as
described by Bacigalupo et al. [14], followed by ATG
in refractory cases. Chronic GVHD (cGVHD) was
treated with prednisone 1 mg/kg/day.
Supportive Care
Patients were nursed in high-efficiency particulate
air (HEPA)-filtered rooms. Intravenous access was
achieved with a double-lumen tunneled central venous
catheter. Granulocyte colony-stimulating factor (G-
CSF) was administered subcutaneously 5 mg/kg/day
from day17 until neutrophil engraftment. All patients
received oral ciprofloxacin (500 mg/12 h) as antibacte-
rial prophylaxis. Prophylaxis against Pneumocystis jiro-
veci consisted of cotrimoxazole (320/1600 mg
trimethoprim/sulfamethoxazole daily) from day 210
to day 22, and then restarted after engraftment to
maintain a minimum of 1 year or until stopping immu-
nosuppresion (2 days a week). Fluconazole (100 mg/
day orally) was administered as antifungal prophylaxis
in some patients at the beginning of the study period.
From November 2003, fluconazole was substituted
by i.v. itraconazole (200 mg/day). All blood products
were irradiated and leukocyte depleted. CMV prophy-
laxis, infection surveillance, and treatment has been
described in detail elsewhere [15]. Nonspecific i.v.
immunoglobulin was administered at a dose of
500 mg/kg weekly until day 1100 and then monthly
during the first year after transplantation.
Definitions
Treatment outcomes were assessed according to
the revised criteria by Cheson et al. [16]. Myeloid en-
graftment was defined as an absolute neutrophil count
(ANC) of 0.5  109/L or greater on 3 consecutive
days. Platelet engraftment was defined as a platelet
count of 20 109/L or higher,without transfusion sup-
port, for 7 consecutive days. Patients who survivedmore than 28 days after transplantation and who failed
to achieve myeloid engraftment were considered as
graft failures. Time to myeloid or platelet engraftment
was defined as the time required to reach the first day of
engraftment. Secondary graft failure was defined as the
loss of the engraftment. aGVHDandcGVHDwerede-
fined and graded according to standard criteria [17-19].
Killer cell immunoglobulin-like receptor (KIR)-ligand
compatibility was defined as described by Willemze
et al. [20]. Briefly, KIR-ligand compatibility in the
graft-versus-host (GVH) direction was determined
according to whether or not they expressed HLA-C
group 1 or 2, HLA-Bw4 [21] or HLA-A3/-A11 [22].
Statistical Analysis
The probability of engraftment, nonrelapse mor-
tality (NRM), GVHD, and relapse was estimated by
the cumulative incidence method (marginal probabil-
ity) [23,24]. For cumulative incidence analysis of en-
graftment, GVHD, and relapse, death in CR was
considered as a competing cause of failure, whereas
for NRM relapse was considered the competing event.
Unadjusted time-to-event analyses were performed
using the Kaplan-Meier estimate [25], and, for com-
parisons, the log-rank tests [26]. Leukemia-free sur-
vival (LFS) was calculated from the date of CBT. In
the analysis of LFS, relapse and death in CR were con-
sidered uncensored events, whichever occurred first.
Variables considered for prognostic factor analysis
were: age, gender, recipient weight, recipient CMV
serology, disease status at transplant, HLA compatibil-
ity, ABO blood group mismatch, donor-recipient sex
match, KIR-ligand incompatibility, year of transplan-
tation, conditioning regimen, GVHD prophylaxis,
and TNC and CD341 cells before freezing and
infused. Continuous variables were dichotomized at
the most discriminative cutoff point for each outcome.
Variables with a value of P\ .10 for each end point
were tested in multivariate analysis using the Cox pro-
portional hazards model for temporal events [27]. The
follow-up of the patients was updated on February 15,
2009. All P-values reported are 2 sided. Except for the
cumulative incidence method, computations were per-
formed using the appropriate programs from the
BMDP statistical library (BMDP Statistical Software,
Los Angeles, CA) [28].RESULTS
Patient Characteristics
Table 2 shows the characteristics of the 49 adult
patients with AML who underwent CBT from unre-
lated donors. Briefly, 30 patients were males and 19
females with a median age of 34 years (range: 16-52
years). Thirty CB recipients (61%) were transplanted
in first CR (CR1). The remaining 19 patients had
Table 2. Characteristics of Patients with AML Undergoing
UCBT*
No. of patients 49
Age, years
Median 34
Range 16-52
Age group, no. (%)
16-20 years 4 (8)
21-30 years 13 (27)
31-40 years 17 (35)
41-50 years 13 (27)
>50 years 2 (4)
Sex, no. (%)
Male 30 (61)
Female 19 (39)
Weight, kg
Median 71
Range 47-112
Disease status at transplant, no. (%)
First complete remission 30 (61)
Second complete remission 6 (12)
Third or subsequent complete remission 2 (5)
Active disease (primary refractory or relapsed leukemia) 11 (22)
Diagnosis
De novo 42 (86)
Therapy- or MDS-related secondary AML 7 (14)
Cytogenetics
Favorable 1 (2)
Intermediate 20 (41)
Poor 19 (39)
Unknown 9 (18)
Previous autologous transplant 5 (10)†
Cytomegalovirus serologic status before transplantation, no. (%)
Positive 37 (75)
Negative 12 (25)
High-risk features for patients in first CR (n 5 30)
Poor risk cytogenetics‡ 6 (20)
$ 2 cycles of induction therapy to achieve CR§ 11 (37)
Poor risk cytogenetics and $2 cycles of induction therapy to
achieve CR
5 (17)
Other§ 8 (27)
Time from diagnosis to transplantation for patients in first CR, mo
Median 6
Range 3.9-9.1
AML indicates acute myelogenous leukemia; CR, complete remission;
MDS,myelodysplastic syndrome; UCBT, umbilical cord blood transplant.
*Percentages may not sum to 100 because of rounding.
†One patient underwent 2 autologous transplants.
‡Poor risk cytogenetics included: complex karyotype, del(7q)/27,
t(6;9), EVI1, t(9;22), MLL rearrangement.
§This is a miscellaneous group including patients with poor mutational
status (n5 3), high minimal residual disease by flow cytometry after in-
duction or consolidation therapy (n 5 3), prior myelodysplastic syn-
drome (n5 1), and biphenotypic leukemiawith t(4;6) and t(7;14) (n5 1).
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Figure 1. Cumulative incidence of neutrophil recovery after CBT,
overall and according to CD341 cells before freezing (cutoff, 1.5 
105/kg).
Biol Blood Marrow Transplant 16:86-94, 2010 89Umbilical Cord Blood Transplant in AMLmore advanced disease status. Patients transplanted in
CR1 had at least 1 of the following poor risk features:
poor prognosis cytogenetics (n 5 11), more than 1
cycle to achieve CR (n 5 11), or several other factors
in the remaining 8. Five patients had failed a previous
autologous stem cell transplantation (ASCT). The
median time from diagnosis to transplantation for
patients transplanted in first CR was 6 months (range,
4 to 9). Median follow-up for surviving patients was
24 months (range: 3 to 79).
Cord Blood Unit and Transplant Characteristics
Table 1 shows the characteristics of CB units and
those related to the transplant procedure.Except for 4 patients who received a fully matched
CB unit, the remaining 44 patients (92%) received an
HLA-mismatched unit. Donor-recipient disparity in
1 and 2 of 6 antigens occurred in 19 patients (39%)
and 25 patients (51%), respectively. One additional
patient (2%) received a 3 antigen mismatched unit.
Themedian number of TNC and CD341 cells infused
was 2.2  107/kg (range: 1-4.4) and 1.2  105/kg
(range: 0.09-6.09), respectively. Data on CD341 cells
before freezing was available in 47 CB grafts, of which
46 (98%) had CD341 cells .0.6  105/kg and 40
(85%) had CD341 cells .1  105/kg, with a median
of 1.6  105/kg. Seven patients (13%) received CB
units with a major ABO blood group mismatch. Four-
teen patients (29%) received KIR-ligand-incompatible
CB units in the GVH direction.
Myeloid Engraftment
One patient died on day 19 after CBT without ev-
idence of myeloid engraftment. One additional patient
had a primary graft failure and underwent a second
transplant from an HLA-mismatched family donor
on day 47 after CBT. The remaining 47 patients expe-
rienced myeloid engraftment at a median time of 20
days (range: 11-57). The cumulative incidence at 57
days of myeloid engraftment was 96% (Figure 1). All
patients with myeloid engraftment showed full donor
chimerism at time of reconstitution.
In univariate analysis, the only variable influencing
time to myeloid engraftment was CD341 cell dose
before freezing with a best cutoff at 1.5  105/kg
(Figure 1). The median time to myeloid engraftment
was 18 and 23 days for patients receiving CB units
with CD341 cells above and below 1.5  105/kg,
respectively (P 5 .009) (Table 3).
Platelet Engraftment
Thirteen patients died between 19 to 250 days
after transplant without platelet engraftment. The
Table 3. Univariate and Multivariate Analysis for Engraftment and Nonrelapse Mortality in Study Population
Myelogenous Engraftment Platelet Engraftment NRM
Univariate Univariate Multivariate Univariate Multivariate
Variable Unfavorable P- Value Unfavorable P- Value P-Value Unfavorable P- Value P-Value
Age .4 .98 .4
Sex .8 .1 .6
Weight .6 .18 .4
CMV serology .6 .4 .3
Disease status at transplant .25 > first CR .04 .2
HLA compatibility .4 5-6/6 .03 .17
ABO blood group mismatch .7 .6 Major .02
Donor-recipient sex match .4 .7 .7
KIR-ligand incompatibility 1 .7 .8
Year of transplantation .4 .3 .37
Conditioning regimen .5 .2 .5
Graft-versus-host disease
prophylaxis
.4 CSA + Pred .001 .3
No. of nucleated cells
before freezing
.4 #2.7  107/kg .017 #3.4 .03 .01
No. of nucleated cells
infused
.98 #2.0  107/kg .03 .1
No. of CD34+ cells before
freezing
#1.5  105/kg .009 #1.5  105/kg .0009 <.0001 2.0  105/kg .08
No. of CD34+ cells infused - .4 #1.6  105/kg .002 .18
CMV indicates cytomegalovirus; KIR, killer cell immunoglobulin-like receptor.
90 Biol Blood Marrow Transplant 16:86-94, 2010J. Sanz et al.remaining 36 patients had platelet engraftment at ame-
dian time of 62 days (range: 19-250). The cumulative
incidence of platelet engraftment was 73% at 250 days.
Univariate analysis showed that disease status at
transplant, degree of HLAmismatch, GVHD prophy-
laxis, and TNC and CD341 cell dose before freezing
and at infusion had a significant impact on the cumu-
lative incidence of platelet recovery (Table 3). In mul-
tivariate analysis, the only variable influencing platelet
recovery was CD341 cell dose before freezing, with
the best cutoff at 1.5 105. The median time to plate-
let engraftment was 85 and 47 days for patients who
received CB units below and above 1.5  105/kg,
respectively.GVHD
aGVHD occurred in 27 of 47 evaluable patients.
The clinical grading of aGVHD was grade I in 15 pa-
tients, grade II in 5 patients, grade III in 5 patients, and
grade IV in 2 patients. The median time to the devel-
opment of aGVHD grade II to IV was 14 days (range:
7-57). The cumulative incidence of grade II to IV and
grade III to IV aGVHD at day 100 after UCBT was
26% and 15%, respectively. Skin involvement was
observed in 25 patients (grade II in 11 and grade III
in 3), intestinal involvement in 9 patients (grade II in
2 and grade III in 2), and liver involvement in 4 patients
(grade II in 1, grade III in 2, and grade IV in 1). Two
patients died of aGVHD grade IV.
Seventeen of 39 patients at risk developed
cGVHD. cGVHDwas limited in 6 patients and exten-
sive in 11 patients. Themedian time to development ofcGVHD was 141 days (range: 99-290). The 2-years
cumulative incidence of overall and extensive cGVHD
was 46% and 30%, respectively. Five patients with ex-
tensive cGVHD (45%) had complete resolution and
discontinuation of immunosuppressive therapy in-
cluding cyclosporine and/or prednisone. One patient
died of pulmonary cGVHD.
No factor was associated with the incidence of
aGVHD grade II to IV or III to IV. The only vari-
able related to higher overall cGVHD was high
TNC infused with the best cutoff at 2.8  107/kg
(P 5 .004).NRM and Causes of Death
Nineteen transplant-related deaths occurred at
a median time of 114 days after transplantation (range:
19 to 2535). The causes of death were infection in
10 patients, GVHD in 3 (2 aGVHD and 1 chronic
GVHD), hemorrhage in 3, secondary malignancy in 2
(1Epstein-Barr virus (EBV)-related postransplant lym-
phoproliferative disorder and 1 AML of donor origin),
and primary graft failure in the remaining patient. Four
of the 10 deaths attributable to infection were bacterial
infections (1 Mycobacterium tuberculosis, 1 Escherichia
coli, 1 Stenotrophomonas maltophilia, and 1 Acinetobacter
baumanii), 5 invasive fungal infections (4 Aspergillus sp
and 1 Candida krusei), and 1 leishmaniasis.
The cumulative incidence ofNRMatday100, and2
years was 18% and 39%, respectively (Figure 2). In
univariate analysis, NRM was significantly associated
with major ABO incompatibility between donor and
recipient, and TNC before freezing #3.4  107/kg
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Figure 2. Cumulative incidence of nonrelapse mortality (NRM) and re-
lapse (RR) after CBT.
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was the only variable significantly associated with
a higher NRM (P5 .01).
Relapse
Nine patients relapsed at a median time of 7.5
months (range: 3 to 32). All relapsing patients died.
The 2 years cumulative incidence of relapse was 19%
(Figure 2). No factor was significantly associated
with relapse rate. There was a trend for a lower relapse
rate in patients receiving fludarabine-based condition-
ing regimens (P5 .1) (Table 4). Of the 11 patients with
extensive cGVHD, leukemia relapse after CBT was
detected in 2 patients.
LFS
Twenty-one patients remained alive and leukemia-
free after CBT at last follow up (range: 3-79 months).
The overall LFS at 2 and 4 years were 42% (95%
cumulative incident [CI], 27% to 57%) and 37%Table 4. Univariate and Multivariate Analysis for Relapse and Leuk
Relapse
Univariate
Variable Unfavorable P- Value
Age .5
Sex .16
Weight .9
CMV serology .4
Disease status at transplantat .36
HLA compatibility .28
ABO blood group mismatch .78
Donor-recipient sex match .6
KIR-ligand incompatibility .7
Year of transplantation .16
Conditioning regimen BUCY .1
Graft-versus-host disease prophylaxis .87
No. of nucleated cells before freezing .9
No. of nucleated cells infused .49
No. of CD34+ cells before freezing .14
No. of CD34+ cells infused .86
CMV indicates cytomegalovirus; KIR, killer cell immunoglobulin-like receptor.(95%CI, 21% to 53%), respectively (Figure 3). In uni-
variate analysis, disease status, HLA mismatch, ABO
incompatibility, and TNC at infusion had a significant
impact on LFS (Table 4). In multivariate analysis
TNC #2  107/kg was the only variable significantly
associated with lower LFS (P 5 .04) (Table 4).
When the analysis was restricted to patients trans-
planted in CR1 (n 5 30), the 4-year overall LFS was
48% (95% CI, 28% to 68%). In this setting, those
patients receiving TNC at infusion above and below
2  107/kg, the 4-year LFS rates were 75% and
25%, respectively (P 5 .03) (Figure 4).DISCUSSION
This single-center study confirms that single-unit
CBT fromunrelated donors aftermyeloablative condi-
tioning is a real alternative for adults with AML for
whomahematopoietic stem cell transplant is indicated.
We were also able to identify CD341 cell dose before
freezing as an independent factor associated with he-
matopoietic recovery, influencing both myeloid and
platelet engraftment. TNC dose was associated with
bothNRMand LFS. These datamay provide clinically
useful information to improve the outcome of CBT in
adults with poor-risk AML through better selection of
both CB units and recipients.
Despite the important growth in CBT activity all
over the world, information on disease-specific out-
comes is still very limited. In fact, only 2 subsequent
reports from the University of Tokyo [6,7] have re-
ported specific data on CBT from unrelated donors
in adults with AML. Two additional registry-based re-
ports, 1 from Eurocord/EBMT [4] and another from
the JMDP/JCBBN [8], have also analyzed CBT out-
come in adults with acute leukemia (AML and ALL),emia-Free Survival in the Study Population
Leukemia-Free Survival
Multivariate Univariate Multivariate
P-Value Unfavorable P- Value P-Value
.7
Male .09
.4
.2
> first CR .04
5-6/6 .02
Major .005
.2
.9
.8
.8
.28
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Figure 3. Kaplan-Meier estimate of leukemia-free survival (LFS) in 49
adults with AML undergoing CBT from unrelated donor.
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BMT. Therefore, our results will be discussed in the
context of this limited information on CBT in adults
with AML.
Regarding the characteristics of patients and CB
units of the present study compared with other similar
reports, it should be noted that the median weight of
patients in our series was higher (71 kg) than reported
by the University of Tokyo [7] and Eurocord [4] (55
and 58 kg, respectively). It can be also highlighted the
higher HLA disparities between donors and recipients
in the Japanese study [7] compared with our series.
Whereaswe transplanted only 1 patient (2%)with 3 an-
tigen mismatches, 35% of patients in the study of the
University of Tokyo had similar or greater incompati-
bility (5%did not share 4HLAantigens). An additional
dissimilarity of our study when compared with the
aforementioned studies is the higher fraction of pa-
tients transplanted in CR1. Nevertheless, all patients
in this setting had at least 1 high-risk feature, with
poor risk cytogenetics and/or $2 cycles of induction
therapy to achieve CR being the most frequent factors
(74%) that led to indicate an allogeneic SCT. For the
remaining patients transplanted in CR1, other factors
that have been recognized to confer bad prognosis0
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Figure 4. Kaplan-Meier estimates of leukemia-free survival (LFS) ac-
cording to total nucleated (TNC) cells infused (cutoff, 2  107/kg) in
30 adults with AML in first CR.were present. This is the case of high minimal residual
disease by flow cytometry after induction and/or con-
solidation [29], or displaying a poor mutational status
[30]. In contrast with the University of Tokyo [7], no
patient in our study was transplanted if they had inter-
mediate cytogenetics only. Because of the potential
impact on several outcomes, dissimilarities in the char-
acteristics of patients andCBunits should be taken into
account to interpret the results of different studies.
In our study, as in that of the University of Tokyo,
hematopoietic recovery in CBT recipients was signifi-
cantly faster and graft failure was lower than in the 3
large registry-based retrospective studies carried out
in Europe [4], Japan [8], and the United States [5].
Whereas the median time to neutrophil recovery was
20 days in our patients and 21 days in the study of the
University of Tokyo, it was 27 and 28 days in 2 of the
aforementioned registry-based studies that provided
these data [4,5]. In addition, myeloid engraftment in
the 2 single institutions were significantly higher
(roughly 95%) than in the registry-based series (range:
70% to 77%). In both single-center studies, we found
that a higher CD341 cell dose before freezing is the
most important factor associated with faster hemato-
poietic recovery. Furthermore, the TNC dose infused
in our patients was similar to other reports in adults
and significantly lower than in pediatric patients [31]
undergoing CBT that used only the nucleated cell
dose content for CB unit selection and resulted in
a slower engraftment than in this report. Therefore,
we can speculate that the selection of CB units with
high number of CD341 cells, a criterion followed in
our institution for guiding CB unit choice, could have
been the main factor contributing to the improvement
in rapidity and rate of engraftment.Unfortunately, data
onCD341 cell dose were not provided by the registry-
based studies to confirm this hypothesis. However, the
role of other factors, such as the conditioning regimen
used, cannot be excluded. In this regard, those strate-
gies designed to improve engraftment such as the use
of 2 CB units [32] or direct intrabone infusion [33]
have reported engraftment results that are not substan-
tially different from our data and should compare with
these single-center studies instead of registry data.
As it has been previously reported [4,5,8,34,35], we
have confirmed a relatively low incidence of aGVHD
and cGVHD after CBT. Only the series reported by
Ooi et al. [7] observed a remarkably high incidence
of aGVHD and cGVHD (81% for aGVHD grade II
to IV and 84% for cGVHD). Nevertheless, it should
be noted that this important difference in GVHD
rate was mainly because of the incidence of aGVHD
grade II and limited cGVHD. Interestingly, in our
study, we found that the degree of HLA mismatch
seems to have no influence on the occurrence of
aGVHD or cGVHD, whereas high TNC dose was as-
sociated with the development of cGVHD.
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shows higher rates (18% at day 100 and 39% at 2 years)
than those reported in the study of the University of
Tokyo (9% at day 100 and 10% at 5 years). However,
the studies by Eurocord/EBMT [4] and the JMDP/
JCBBN [8] reported cumulative incidence of TRM
at 2 years of 44% (for AML and ALL together) and
33% (for AML), respectively. Trying to scrutinize
the reasons that might explain this difference in
NRM, several factors should be considered. First, we
found all the 5 patients with a previous autologous
stem cell transplantation died, and also, the study of
the University of Tokyo did not include patients pre-
viously autografted. An additional aspect to take into
account is the higher mortality because of infection
and hemorrhage observed in our study. Apart from
some local factors, it is possible that the implementa-
tion of stricter preventive and therapeutic measures
to manage infectious complications, with high impact
in mortality [36], could improve outcomes.
Relapse rate was low and similar to the rates previ-
ously reported for patients with high- risk AML in the
setting of bone marrow unrelated donor transplant
[37] and CBT [7], confirming the high antileukemic
efficacy of the procedure. Hence, overall long-term re-
sults in terms of event-free survival (EFS) were mainly
influenced by NRM and the associated risk factors.
In conclusion, these results show that single-unit
CBT from unrelated donors after MA conditioning
is a curative treatment for a substantial number of pa-
tients with high-risk AML, particularly if transplant is
performed with highly cellular units in patients in first
CR. Cell dose should be the most important factor to
consider when selecting CB units, both in terms of
TNC andCD341 cells.More specific studies on adults
with AML receiving CBT from unrelated donors are
warranted to definitely establish the best donor and pa-
tients conditions that improve outcome and place this
procedure in the therapeutic algorithm of this disease.
ACKNOWLEDGMENTS
The authors thank Shirley Weiss for data collec-
tion and management. Contributions: J.S., M.S., and
G.S., conceived the study and interpreted the data;
J.S., M.S., and G.S. wrote the paper; J.S. performed
the statistical analyses; S. S., I. L., P.M., L.S., D.P.,
L. L., G. M., J. P., I. J., J. M., J. R., F. M., M. R., I.
L., A. M., and S. C. reviewed the manuscript and con-
tributed to the final draft.
Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Sanz MA. Cord-blood transplantation in patients with leuke-
mia—a real alternative for adults. N Engl J Med. 2004;351:
2328-2330.2. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes
of unrelated bone marrow and umbilical cord blood transplants
in children with acute leukemia. Blood. 2001;97:2962-2991.
3. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of trans-
plantation of unrelated donor umbilical cord blood and bone
marrow in children with acute leukaemia: a comparison study.
Lancet. 2007;369:1947-1954.
4. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-
cord blood or bone marrow from unrelated donors in adults
with acute leukemia. N Engl J Med. 2004;351:2276-2285.
5. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after
transplantation of cord blood or bone marrow from unrelated
donors in adults with leukemia. N Engl J Med. 2004;351:
2265-2275.
6. Ooi J, Iseki T, Takahashi S, et al. Unrelated cord blood trans-
plantation for adult patients with de novo acute myeloid leuke-
mia. Blood. 2004;103:489-491.
7. Ooi J, Takahashi S, Tomonari A, et al. Unrelated cord blood
transplantation after myeloablative conditioning in adults with
acute myelogenous leukemia. Biol Blood Marrow Transplant.
2008;14:1341-1347.
8. Atsuta Y, Suzuki R, Nagamura-Inoue T, et al. Disease-specific
analyses of unrelated cord blood transplantation compared
with unrelated bone marrow transplantation in adult patients
with acute leukemia. Blood. 2009;113:1631-1638.
9. Rubinstein P, Dobrila L, Rosenfield RE, et al. Processing and
cryopreservation of placental/umbilical cord blood for unrelated
bone marrow reconstitution. Proc Natl Acad Sci U SA. 1995;92:
10119-10122.
10. Sanz GF, Saavedra S, Jimenez C, et al. Unrelated donor cord-
blood transplantation in adults with chronic myelogenous
leukemia: results in nine patients from a single institution.
Bone Marrow Transplant. 2001;27:693-701.
11. McNiece I, Kern B, Zilm K, Brunaud C, Dziem G, Briddell R.
Minimization of CD341 cell enumeration variability using the
ProCOUNT standardized methodology. J Hematother. 1998;
7:499-504.
12. Mossuz P, Dobo I, GenewayMC, et al. Use of collagen for stan-
dardization of PBSC graft quality evaluation: amulticenter com-
parative analysis of commercial collagen-based and
methylcellulosebased colony-forming unit (CFU) assay kits.
J Hematother. 1998;7:351-359.
13. Sanz GF, Saavedra S, Planelles D, et al. Standardized, unrelated
donor cord blood transplantation in adults with hematologic
malignancies. Blood. 2001;98:2332-2338.
14. Bacigalupo A, van Lint MT, Frassoni F, et al. High dose bolus
methylprednisolone for the treatment of acute graft versus
host disease. Blut. 1983;46:125-132.
15. Montesinos P, Sanz J, Cantero S, et al. Incidence outcome and
risk factors of cytomegalovirus infection and disease after umbil-
ical cord-blood transplantation in adult patients. Biol Blood
Marrow Transplant. Biol Blood Marrow Transplant. 2009;15:
730-740.
16. Cheson BD, Bennett JM, Kopecky K, et al. Revised Recommen-
dations of the International Working Group for Diagnosis,
Standardization of Response Criteria, Treatment Outcomes,
and Reporting Standards for Therapeutic Trials in Acute Mye-
loid Leukemia. J Clin Oncol. 2003;21:4642-4649.
17. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of
graft-versus-host disease in human recipients of HLA-matched
sibling donors. Transplantation. 1974;18:295-304.
18. Przepiorka D, Weisdorf D, Martin P, et al. Consensus confer-
ence on acute GVHD grading. Bone Marrow Transplant. 1995;
15:825-828.
19. Shulman HM, Sullivan KM, Weiden PI, et al. Chronic graft-
versus-host syndrome in man: a long-term clinicopathologic
study of 20 Seattle patients. Am J Med. 1980;69:204-217.
20. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand in-
compatibility in the graft-versus-host direction improves out-
comes after umbilical cord blood transplantation for acute
leukemia. Leukemia. 2009;23:492-500.
94 Biol Blood Marrow Transplant 16:86-94, 2010J. Sanz et al.21. Ruggeri L, Capanni M, Mancusi A, et al. Alloreactive natural
killer cells in mismatched hematopoietic stem cell transplanta-
tion. Blood Cells Mol Dis. 2004;33:216-221.
22. Hansasuta P, Dong T, Thananchai H, et al. Recognition of
HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific.
Eur J Immunol. 2004;34:1673-1679.
23. Gooley TA, Leisenring W, Crowley JA, Storer BE. Estimation
of failure probabilities in the presence of competing risks: new
representations of old estimators. Stat Med. 1999;18:665-706.
24. Fine JP, Gray RJ. A proportional hazards model for subdistribu-
tion of a competing risk. J Am Stat Assoc. 1999;94:496-509.
25. Kaplan EL, Meier P. Nonparametric estimation from incom-
plete observations. J Am Stat Assoc. 1958;53:457-481.
26. Mantel N. Evaluation of survival data and two new rank order
statistics arising in its consideration. Cancer Chemother Rep.
1966;50:163-170.
27. Cox DR. Regressionmodels and life tables (with discussion). J R
Stat Soc B. 1972;34:187-220.
28. Dixon WJ. BMDP Statistical Software. Berkeley, CA: University
of California Press; 1990.
29. KernW,Haferlach C,Haferlach T, Schnittger S.Monitoring of
minimal residual disease in acute myeloid leukemia. Cancer.
2008;112:4-16.
30. Schlenk RF, Do¨hner K, Krauter J, et al. Mutations and treat-
ment outcome in cytogenetically normal acute myeloid leuke-
mia. N Engl J Med. 2008;358:1909-1918.31. Kurtzberg J, Prasad VK, Carter SL, et al. Results of the Cord
Blood Transplantation Study (COBLT): clinical outcomes of
unrelated donor umbilical cord blood transplantation in pediatric
patients with hematologic malignancies. Blood. 2008;112:
4318-4327.
32. Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of
two partially HLA-matched umbilical cord blood units to en-
hance engraftment in adults with hematologic malignancy.
Blood. 2005;105:1343-1347.
33. Frassoni N, Gualandi F, Modesta M, et al. Direct intrabone
transplant of unrelated cord-blood cells in acute leukaemia:
a phase I/II study. Lancet Oncol. 2008;9:831-839.
34. Arcese W, Rocha V, Labopin M, et al. Unrelated cord blood
transplants in adults with hematologic malignancies. Haemato-
logica. 2006;91:223-230.
35. MacMillan ML, Weisdorf GJ, Brunstein CG, et al. Acute
graft-versus-host disease after unrelated donor umbilical cord
blood transplantation: analysis of risk factors. Blood. 2009;113:
2410-2415.
36. Yazaki M, Atsuta Y, Kato K, et al. Incidence and risk factors of
early bacterial infections after unrelated cord blood transplanta-
tion. Biol Blood Marrow Transplant. 2009;15:439-446.
37. Sierra J, Storer B, Hansen JA, et al. Unrelated donor
marrow transplantation for acute myeloid leukemia: an update
of the Seattle experience. Bone Marrow Transplant. 2000;26:
397-404.
